21 CFR § 862.3645 - Neuroleptic drugs radioreceptor assay test system.

---
identifier: "/us/cfr/t21/s862.3645"
source: "ecfr"
legal_status: "authoritative_unofficial"
title: "21 CFR § 862.3645 - Neuroleptic drugs radioreceptor assay test system."
title_number: 21
title_name: "Food and Drugs"
section_number: "862.3645"
section_name: "Neuroleptic drugs radioreceptor assay test system."
chapter_name: "FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES"
subchapter_number: "H"
subchapter_name: "MEDICAL DEVICES"
part_number: "862"
part_name: "CLINICAL CHEMISTRY AND CLINICAL TOXICOLOGY DEVICES"
positive_law: false
currency: "2026-04-05"
last_updated: "2026-04-05"
format_version: "1.1.0"
generator: "[email protected]"
authority: "21 U.S.C. 351, 360, 360c, 360e, 360j, 360 371."
regulatory_source: "52 FR 16122, May 1, 1987, unless otherwise noted."
cfr_part: "862"
---


# 862.3645 Neuroleptic drugs radioreceptor assay test system.

(a) *Identification.* A neuroleptic drugs radioceptor assay test system is a device intended to measure in serum or plasma the dopamine receptor blocking activity of neuroleptic drugs and their active metabolites. A neuroleptic drug has anti-psychotic action affecting principally psychomotor activity, is generally without hypnotic effects, and is a tranquilizer. Measurements obtained by this device are used to aid in determining whether a patient is taking the prescribed dosage level of such drugs.

(b) *Classification.* Class II.